Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12620000031965
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
18/12/2019
Date registered
Help: Date registered
20/01/2020
Date last updated
Help: Date last updated
25/08/2026
Date data sharing statement initially provided
Help: Data sharing statement date
20/01/2020
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A study to investigate if melatonin can improve sleep in hospital after abdominal surgery or Orthopaedic Surgery, including Hips and Knees.
Scientific title
Melatonin to Improve Sleep in Patients Undergoing Major Abdominal Surgery or Orthopaedic Surgery, including Hips and Knees: A Double-blind, Randomised Placebo-controlled Trial
Additional trial identifiers [1] 300066 0
None
Universal Trial Number (UTN)
Trial acronym
Melrose
Related trial records

Health condition
Health condition(s) studied:
Abdominal surgery 315585 0
Sleep disturbance 315586 0
Condition category
Condition code
Surgery 313871 313871 0 0
Other surgery
Alternative and Complementary Medicine 314059 314059 0 0
Other alternative and complementary medicine
Musculoskeletal 338829 338829 0 0
Other muscular and skeletal disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Melatonin 5mg wafer once daily sublingual whilst in hospital from day 1 post surgery up to 7 days or until discharge if prior to 7 days. The doses will be prescribed via the electronic medication chart and this will be reviewed to confirm compliance to administration.
Intervention code [1] 316333 0
Treatment: Drugs
Description of the comparator or control
Placebo 1 wafer once daily sublingual whilst in hospital up to 7 days or until discharge if prior to 7 days. The placebo will consist of a starch.
Control group
Placebo

Outcomes
Primary outcome [1] 322352 0
The primary efficacy outcome is a difference in Patient-Reported Outcome Measurement Information System (PROMIS) Sleep Disturbance 8a score between the 2 arms of the study.
Timepoint [1] 322352 0
At day 3 post surgery.
Secondary outcome [1] 378184 0
Mean difference between groups for serum cortisol levels
Timepoint [1] 378184 0
Levels measured at baseline, day of surgery and day 1, 2, 3 post-operatively as recorded from the medial record.
Secondary outcome [2] 378185 0
Incidence of post-operative surgical complications graded by the Clavien-Dindo Classification of Surgical Complications.
Timepoint [2] 378185 0
Up to day 30 post-op as recorded in medical record.
Secondary outcome [3] 378186 0
Difference between groups for mean length of hospital stay (days)
Timepoint [3] 378186 0
As recorded in medical record for index admission, up to the time of suitability for surgical discharge to home or rehabilitation.
Secondary outcome [4] 378187 0
All-cause mortality
Timepoint [4] 378187 0
By day 30 as recorded in medical record or reported by treating surgeon.
Secondary outcome [5] 378188 0
Incidence of delirium as defined by a clinical diagnosis of same by treating team.
Timepoint [5] 378188 0
Assessed from the medical record up to the time of hospital discharge or discharge from surgical service.
Secondary outcome [6] 378189 0
Patient reported quality of life scores
Timepoint [6] 378189 0
Measured pre-operatively and at day 30 post-op using the EQ-5D-5L.

Eligibility
Key inclusion criteria
All English-speaking patients 18 years and over undergoing elective/semi-elective major abdominal surgery or orthopaedic surgery (hip and knee resplacement) with an anticipated length of stay greater than 48 hours.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Patients from the above group will be excluded if they:
• Are unable to give written informed consent to take part in the study,
• Patients who require the use of a trained healthcare interpreter to be able to understand study information.
• Lack decision-making capacity,
• Expected stay less than 48 hours,
• Concurrent use of benzodiazepine, non-benzodiazepine (Z-drugs) or melatonin,
• Alcohol consumption > 13 units/week for women and >20 units/week for men.
• Currently taking melatonin
• Drug interaction with melatonin.
• Allergy to melatonin or its excipients (may contain lactose)
• Decreased renal function as defined by an eGFR of <30 mL/min/1.73m2
• Decreased liver function defined as an AST > 500 U/L or ALT >500 U/L
• Pregnant or breastfeeding females
• Enrolment in other clinical trials involving an investigational agent
• Taking quinolones, carbamazepine and rifampicin, fluvoxamine, 5- or 8- methoxypsoralen, cimetidine, oestrogens.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Central randomisation by computer
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Permuted block randomisation
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Efficacy
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Date of first participant enrolment
Anticipated
17/08/2020
Actual
17/08/2020
Date of last participant enrolment
Anticipated
17/08/2023
Actual
20/09/2023
Date of last data collection
Anticipated
1/12/2026
Actual
Sample size
Target
340
Accrual to date
Final
340
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 15529 0
John Hunter Hospital - New Lambton
Recruitment postcode(s) [1] 28899 0
2305 - New Lambton

Funding & Sponsors
Funding source category [1] 304515 0
Hospital
Name [1] 304515 0
John Hunter Hospital
Country [1] 304515 0
Australia
Primary sponsor type
Government body
Name
Hunter New England Local Health District.
Address
Lookout Road
New Lambton Heights NSW 2305
Country
Australia
Secondary sponsor category [1] 304784 0
None
Name [1] 304784 0
Address [1] 304784 0
Country [1] 304784 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 304946 0
Hunter New England Human Research Ethics Committee
Ethics committee address [1] 304946 0
Ethics committee country [1] 304946 0
Australia
Date submitted for ethics approval [1] 304946 0
29/11/2019
Approval date [1] 304946 0
18/12/2019
Ethics approval number [1] 304946 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 98726 0
Dr Eduard Martinez
Address 98726 0
Intensive Care Unit John Hunter Hospital Locked Bag 1 Hunter Region Mail Centre NSW 2310
Country 98726 0
Australia
Phone 98726 0
+61 0249236397
Fax 98726 0
Email 98726 0
[email protected]
Contact person for public queries
Name 98727 0
Natalie Lott
Address 98727 0
Surgical Services John Hunter Hospital Locked Bag 1 Hunter Region Mail Centre NSW 2310
Country 98727 0
Australia
Phone 98727 0
+61 0418215968
Fax 98727 0
Email 98727 0
[email protected]
Contact person for scientific queries
Name 98728 0
Eduard Martinez
Address 98728 0
Intensive Care Unit John Hunter Hospital Locked Bag 1 Hunter Region Mail Centre NSW 2310
Country 98728 0
Australia
Phone 98728 0
+61 0249236397
Fax 98728 0
Email 98728 0
[email protected]

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers
Conditions for requesting access:
• Yes, conditions apply:
• Requires review on a case-by-case basis by the trial custodian, sponsor or data sharing committee
• Requires a scientifically sound proposal or protocol
• Requires approval by an ethics committee
• Requires a data sharing agreement between data requester and trial custodian or sponsor
What individual participant data might be shared?
• All de-identified individual participant data
What types of analyses could be done with individual participant data?
• Systematic reviews and meta-analyses
• Studies exploring new research questions
• Health economic analyses
• Teaching research methods or developing new statistical techniques
When can requests for individual participant data be made (start and end dates)?
From:
After publication of main results
To:
No end date
Where can requests to access individual participant data be made, or data be obtained directly?
• Data sharing request system: Hunter Medical Research Institute (HMRI) REDCap

• Email of trial custodian, sponsor or committee: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.